VIENNA, VA, November 27, 2019
/24-7PressRelease/ -- Prof. Salwa Elgebaly has been included in Marquis Who's
Who. As in all Marquis Who's Who biographical volumes, individuals profiled are
selected on the basis of current reference value. Factors such as position,
noteworthy accomplishments, visibility, and prominence in a field are all taken into
account during the selection process.
The U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug
Designation to Nour
Heart's new drug Cyclocreatine Phosphate for the prevention of ischemic
injury to enhance cardiac graft recovery and survival in heart
transplantation (DRU-2015-4951).
A research professional in the biomedical field, Prof. Elgebaly excels as the
founder and the chief executive officer of Nour Heart, Inc., where she handles
research and development for heart-related diagnostic and therapeutic products,
conducts clinical trials in pharmaceutical set-up and investigative sites and
submits products to the FDA for approval. Her research has resulted in the discovery
of the heart-derived inflammatory mediator, Nourin as an early laboratory
biomarker for the quick diagnosis of heart patients experiencing chest pain, and
thus, allowing crucial therapy to save heart muscles. Her research further
identified Cyclocreatine Phosphate as a potent cardioprotective drug aimed at
protecting heart patients against ischemic injury, and also, the anti-inflammatory
agent Cyclosporin H which protects hearts against inflammation-induced injury. Prof.
Elgebaly has written a Review article on the cardioprotective benefits of
Cyclocreatine Phosphate which was published in the Journal of Expert Review of
Cardiovascular Therapy in September 2019. She is a sole inventor and
contributor to nine patents issued by the U.S. Patent Office in Washington DC and,
also, inventor on one pending application. Prof. Elgebaly has been the Principal
Investigator on 33 research grants totaling nearly $7 million in funding. Prof.
Elgebaly is also the recipient of the 2016 and 2018 "Jesor" grants from the Egyptian
Academy of Scientific Research and Technology in conjunction with Cairo University
and Helwan University, Cairo, Egypt.
Prof. Elgebaly's work was selected by Expert Panel to appear in the 2013
CardioValens.com under the title: A new powerful and early marker of myocardial
ischemia/reperfusion – cardiac Nourin and her patent was included in the
Immunology Chapter of Dr. Ashton Acton's Scholarly book entitled: Acute
Myocardial Infarction: New Insights for the Health Care Professional, 2013
Edition.
Prior to founding Nour Heart, she had gained valuable expertise in Nourin technology
as the director of the Nourin Pre-clinical and Clinical Development Program, the
director of clinical affairs for AnGes, Inc. and the director of clinical trials and
research for the Connecticut Multispecialty Group during the early 2000s.
Previously, Dr. Elgebaly worked as the director of clinical trials and research for
Grove Hills Medical Center from 1998 to 2000, and in numerous educational positions
at the University of Connecticut School of Medicine from 1979 to 1997 (Postdoc,
Instructor, Assistant Professor, Associate Professor and Director of Surgical
Research).
After earning a Bachelor of Science in pharmacy from the University of Alexandria
Faculty of Pharmacy in Egypt in 1973, Dr. Elgebaly relocated to the United States in
pursuit of higher education. She later completed a postdoctoral fellowship and
obtained a Master of Science in oncology and cancer biology at the University of
Wisconsin. In 1979, Dr. Elgebaly graduated with a Doctor of Philosophy in oncology
and cancer biology at the University of North Carolina, Chapel Hill (ranked number 1
in the world).
A devoted industry and community advocate, Prof. Elgebaly is active as a scientific
reviewer for Bibliotheca Alexandria Research Grants and Special Projects and the
founder of the Clinical Research Center (CRC) at the University of
Alexandria Faculty of Medicine to conduct FDA-regulated Clinical Trials. Due to her
considerable expertise, she has been invited to speak and function as a consultant
on FDA-regulated clinical trials and International Guidelines and Regulations.
Likewise, Dr. Elgebaly found success as the chair of the Maryland conference
entitled American Muslim Women sponsored by Commissioner for Women
through Anne Arundel County. She also served as a member of the Governor's
Commission on Middle Eastern American Affairs, Maryland.
Prof. Elgebaly is a frequent Invited Speaker at international cardiology
conferences and presented her work in many scientific conferences worldwide
including: the American College of Surgeons, American Heart Association, American
Association of Immunologists, International Society for Heart Research (ISHR) and
Society for Cardiovascular Angiography and Interventions. She has been most honored
by invitations to present her unique work from two Nobel Prize Winner in Medicine,
Professor Sir John Vane, London, United Kingdom and Professor R. Levi Montalcini,
Rome, Italy and Professor Sir Dr. Magdy Yacoub in London, United Kingdom.
Prof. Elgebaly published many peer-reviewed papers in respected journals including:
Science, J. Thoracic & Cardiovascular Surgery, J. Molecular and Cellular
Cardiology, J. Pathology, J Expert Review of Cardiovascular Therapy, J.
Transplantation, J. Urology, J Pharmacology Experimental Therapy, American Journal
of National Cancer Institute, and Journal of Ophthalmology and Visual Science and a
Review article entitled Cyclocreatine Protects Against Ischemic Injury
and Enhances Cardiac Recovery During Early Reperfusion published in the
Journal of Expert Review of Cardiovascular Therapy, 17(9), 683-697, 2019.
Looking toward the future, Prof. Elgebaly intends to continue her work by developing
a diagnostic test and medication aimed at helping people prone to heart attacks
through early diagnosis and treatment.
About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®,
Marquis Who's Who® has chronicled the lives of the most accomplished individuals and
innovators from every significant field of endeavor, including politics, business,
medicine, law, education, art, religion and entertainment. Today, Who's Who in
America® remains an essential biographical source for thousands of researchers,
journalists, librarians and executive search firms around the world. Marquis® now
publishes many Who's Who titles, including Who's Who in America®, Who's Who in the
World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who
in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be
visited at the official Marquis Who's Who® website at
VIENNA, VIRGINIA, UNITED STATES, January 27, 2020 /EINPresswire.com/ -- There are 250,000 people with end-stage heart failure who could qualify for a heart transplant, but only 2,500-3,000 transplants are performed each year. There have been few innovations that could actively expand the donor pool, but a new drug could change the scope of heart transplantation for years to come. Dr. Salwa A. Elgebaly, PhD is the Founder and CEO of Nour Heart, Inc., dedicated to the development of the new cardioprotective drug, Cyclocreatine Phosphate for patients with Ischemic Heart Diseases. “I wanted to bring this to life for the people whose stories touched me,” says Dr. Elgebaly. “I believe in Cyclocreatine phosphate.”
Read MoreProf. Salwa A. Elgebaly Celebrated for Dedication to the Field of Cardiovascular Medicine. Prof. Elgebaly founded Nour Heart, Inc. in 2006 to pursue research into heart-related diagnostic and therapeutic products and is a Professor at the University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, U.S.
Read MoreThe aim of Nour Heart is to develop Cyclocreatine Phosphate as a new cardioprotective drug for patients with ischemic heart disease. She is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and two pending applications.
In 2005, Dr. Elgebaly initiated and was instrumental in implementing the establishment of the first Clinical Research Center (CRC) at Alexandria Faculty of Medicine to conduct all phases of FDA-regulated clinical trials. The CRC celebrated its tenth year in 2016 as the best in Egypt and Middle East according to international pharmaceutical companies. Dr. Elgebaly serves as a volunteer Consultant in the CRC.